- No split in SP; Mulayam rules out forming new party as of now
- Refused open-jeep roadshow, Rahul's Gujarat campaign begins with bullock-cart yatra
- Sports Ministry recommends shuttler Sindhu for Padma Bhushan
- Crackdown on BHU students: Two police officials removed
- Mukul Roy announces resignation from TMC
- Trump announces new travel restrictions, includes N.Korea
HEALTH & FITNESS
Apollo Hospitals ties up with RMS Regrow for cell-based therapy
Apollo Hospitals has partnered with Mumbai-based Regenerative Medical Services (RMS) Regrow to offer a safe and cost-effective cell therapy for cartilage and bone problems for the first time in India.
The partnership will make the cell-based treatment available across all 40 centres of Apollo Hospitals, including Apollo Spectra Hospitals and Apollo clinics in India, the hospital chain said at an event here on Monday.
RMS Regrow, the first "Make in India" company in cell therapy technology, has two treatments: Chondron ACI for knees or cartilage problems and Ossron Autologous Osteoblast Implantation (ABI) for hip joints.
"Nearly 65-70 per cent of people above the age of 40 experience joint problems. The cell therapy may help postpone the need for a replacement surgery and with proper rehabilitation it will also enable a patient to resume normal routine in nearly three months," Prathap C Reddy, Founder-Chairman of Apollo Hospitals told the media.
With the cell-therapy technique, damage to the cartilage can be repaired after the new cultured cartilage is put back into one's knees.
However, for individuals at an advanced stage of osteoarthritis, replacement surgeries will be the best mode of treatment as their cartilages may not be able to regrow.
"Both Ossron and Chondron are efficient in treating a young arthritic knee with sports injuries, accidents and can is an alternative treatment to hip replacements or knee replacements," said Satyen Sanghavi, Chief Scientific Officer at RMS Regrow.
"In the future, the cell therapy-based treatment can also be extended to lengthening of limbs or bones or for maxillofacial defects (defects of the head and neck)," he added.
The company also received a market authorisation approval from the Drug Controller General of India (DGCI) in April this year.
Further, the treatment cost "in India, will be Rs 3.5-4 lakh per patient, which is less than 10 per cent of the cost abroad and will be available in all our hospitals in six months," Reddy said.
- Microsoft opens AI-based healthcare department 25 Sep 2017 | IANS
- Multi-gene test found effective in predicting Alzheimer's disease 24 Sep 2017 | IANS
- What causes bone loss in elderly 24 Sep 2017 | IANS
- Jawbone disorder can worsen migraine 24 Sep 2017 | IANS
- Smartphone apps may help treat depression: study 23 Sep 2017 | IANS
- New genetic syndrome causing cancer identified 23 Sep 2017 | IANS
- Aaron Carter checking into rehab to 'improve his health' 23 Sep 2017 | PTI
- WHO control room in Cox's Bazar for health response to Rohingyas 22 Sep 2017 | IANS
- Cigarette butts to eliminate mosquitoes? 22 Sep 2017 | IANS
- Heavy drinking in college lowers job prospects later: Study 22 Sep 2017 | IANS
Sunday EditionView All
24 Sep 2017 | AFP | Berlin
Chancellor Angela Merkel and her rival Martin Schulz rallied voters on the eve of Sunday’s vote, urging Germans to shun the first hard-right party expected to enter parliament in force since the end of World War II. Merkel, the clear frontrunner after 12 years in power with a double-digit lead, also told her conservative base not to get complacent and to cast their ballots, rousing them with a folksy call to...
STATE EDITIONSView All
25 Sep 2017 | PNS | Indore
To observe the third anniversary of Swacchta Bharat Mission, various events are being held in city. Indore Mayor Malini Laxman Singh Gaud and Indore Municipal Corporation (IMC) Commissioner Manish Singh have instructed to organize events marking the D-day, ie October 2...